NeuroOne amends CEO & three other execs' change-in-control severance benefits

NEUROONE MEDICAL TECHNOLOGIES Corp

CEO Rosa: 2.0x base salary + 2.0x target bonus lump sum, full equity vest, 24-month COBRA upon qualifying termination.
CFO McClurg, COO Volker, CTO Mertens: 1.25x base + 1.25x bonus lump sum, full vest, 15-month COBRA.
Amendments effective Sep 9, 2024; apply to terminations within 12 months after or 3 months before a change in control.
Benefit conditioned on signing a release and ongoing compliance; all other employment terms unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.